<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323646</url>
  </required_header>
  <id_info>
    <org_study_id>ZPV-201</org_study_id>
    <nct_id>NCT02323646</nct_id>
  </id_info>
  <brief_title>A Phase 2, Study to Evaluate the Safety and Efficacy Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Uterine Fibroids</brief_title>
  <official_title>A Phase 2, Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the safety and efficacy of two vaginal
      doses of Proellex administered for up to 2 courses of treatment (18 weeks each), each
      separated by an Off-Drug Interval (ODI), to premenopausal women with symptomatic uterine
      fibroids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects who become amenorrheic after one course of treatment</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6 mg Proellex® (Telapristone Acetate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg Proellex® (Telapristone Acetate) vaginal suppository</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 mg Proellex® (Telapristone Acetate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 mg Proellex® (Telapristone Acetate) vaginal suppository</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Safety and efficacy comparison of 6 mg and 12 mg for 2, 18 week courses of treatment for uterine fibroids</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proellex 6 mg</intervention_name>
    <description>Safety and efficacy comparison of 6 mg and 12 mg for 2, 18 week courses of treatment for uterine fibroids</description>
    <arm_group_label>6 mg Proellex® (Telapristone Acetate)</arm_group_label>
    <other_name>Telapristone Acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proellex 12 mg</intervention_name>
    <description>Safety and efficacy comparison of 6 mg and 12 mg for 2, 18 week courses of treatment for uterine fibroids</description>
    <arm_group_label>12 mg Proellex® (Telapristone Acetate)</arm_group_label>
    <other_name>Telapristone Acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Otherwise healthy adult females between 18 and 47 years

          -  Subject has a history of at least 3 regular menstrual cycles in which menorrhagia is
             due to uterine fibroids.

          -  Subject must have uterine fibroids.

          -  Agreement not to attempt to become pregnant during the trial

          -  Agreement to use only sanitary pads provided throughout the course of the study,
             tampon use is prohibited

          -  Ability to complete a daily subject diary and study procedures in compliance with the
             protocol

          -  Has a negative pregnancy test at the Screening and Baseline visits, and subsequent
             study visits

          -  A Body Mass Index (BMI) between 18 and 45 inclusive

          -  Confirmed &gt; 80 mL of menstrual blood loss caused by uterine fibroids

        Exclusion Criteria:

          -  Subject is a post-menopausal woman, defined as either; six (6) months or more
             (immediately prior to screening visit) without a menstrual period, or prior
             hysterectomy and/or oophorectomy.

          -  Subject is pregnant or lactating or is attempting or expecting to become pregnant
             during the entire study period

          -  Received an investigational drug in the 30 days prior to the screening for this study

          -  Subject has a history of PCOS

          -  Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids,
             DHEA or hormonal products for at least 2 weeks prior to screening and during the study

          -  Use of oral contraceptives in the preceding 30 days. Use of Depo-Provera® in the
             preceding 10 months.

          -  Use of GnRHas (e.g. Lupron Depot) within 3 months of the first dose of study drug
             (Lupron Depot must have a wash-out period of 3 months)

          -  Has an IUD in place

          -  Known or suspected carcinoma of the breast or reproductive organs

          -  Recent history (within past 6 months) of alcoholism or drug abuse

          -  Clinically significant abnormal findings on screening examination and laboratory
             assessments or any condition which in the opinion of the investigator would interfere
             with the participant's ability to comply with the study instructions or endanger the
             participant if she took part in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>47 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235-4759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uterine fibroids</keyword>
  <keyword>leiomyoma</keyword>
  <keyword>fibroid tumor</keyword>
  <keyword>fibroma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

